It is reasonable to hypothesize that based on mechanistic studies to the role of XIAP in cancer and non-malignant conditions (Daoud et al. 2022; Goncharov et al. 2018; Kashkar et al. 2006) increased tumor XIAP level trigger the recruitment of myeloid derived cells to the tumor which modulates the anti-tumor immune response. This evidence concerns the gene XIAP and neoplasm.